Clinical trial
A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
NCT00911898
Study timeline
Study start (unknown)2009-06-01Date precision: month
Registry last updated2015-01-13
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Her2 Amplified Solid Tumorsunresolved
Metastatic Breast Cancerunresolved
Interventions
MM-111DRUG
Sponsors & collaborators
Merrimack Pharmaceuticalslead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00911898 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.